bullish
Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business
339 Views14 Jul 2022 23:09
SUMMARY
- Piramal Enterprises (PIEL IN) obtained shareholders nod for demerging its pharma business and consolidated under Piramal Pharma Limited (PPL). Later, PPL will be listed on India stock exchange.
- PPL has a differentiated pharmaceutical business model, with three business verticals. CDMO, the largest revenue contributor, has track record of consistent above-market growth due to its niche and complex capabilities.
- Listed as a separate entity, PPL will see multiple expansion and command premium valuation over other Indian generic drug makers, due to its niche and limited competition portfolio.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business14 Jul 2022
- 2022 High Conviction | Piramal Enterprises: Demerger to Unlock Value23 Dec 2021
- Positioning itself as a large Retail HFC; Pharma margin would improve in 2HFY2213 Nov 2021
x